Valuation: Regeneron Pharmaceuticals, Inc.

Market Cap 67.96B 59.44B 54.83B 50.64B 96.09B 6,481B 97.7B 655B 257B 3,193B 255B 250B 10,976B P/E 2026 *
17.3x
P/E 2027 * 13.9x
Enterprise Value 60.12B 52.59B 48.51B 44.8B 85.01B 5,734B 86.44B 580B 228B 2,825B 226B 221B 9,711B EV / Sales 2026 *
3.79x
EV / Sales 2027 * 3.27x
Free-Float
72.33%
Yield 2026 *
0.58%
Yield 2027 * 0.66%
1 day-0.51%
1 week+1.57%
Current month+6.57%
1 month+10.45%
3 months-11.26%
6 months-16.58%
Current year-13.91%
1 week 637.72
Extreme 637.715
677.92
1 month 594.9
Extreme 594.9
677.92
Current year 591.52
Extreme 591.52
821.11
1 year 541
Extreme 541
821.11
3 years 476.49
Extreme 476.4869
1,211.2
5 years 476.49
Extreme 476.4869
1,211.2
10 years 271.37
Extreme 271.37
1,211.2
Manager TitleAgeSince
President 66 31/12/2000
Chief Executive Officer 73 07/01/1988
Director of Finance/CFO 55 04/02/2024
Director TitleAgeSince
Chairman 73 08/06/2023
Director/Board Member 85 31/05/1991
Director/Board Member 85 31/05/1991
Date Insider Type Main position Quantity % Market Cap.
07-01Sell

Director

-200 0.0002%
04-30Sell

Director

-100 0.0001%
03-31Sell

Director

100 0.0001%
Change 5-day change 1-year change 3-year change Capi.($)
-0.51%+1.57%+18.72%-5.52% 67.96B
-5.16%-8.63%+37.37%+202.27% 54.4B
-2.10%+0.89%-49.30%-53.47% 41.74B
+5.28%+39.50%+39.50%+39.50% 40.63B
-10.83%-14.41%+99.15%-44.54% 30.38B
+0.12%-7.85%+47.16%-29.27% 29.37B
-1.53%-0.13%+65.92%+88.58% 23.68B
+3.88%+2.16%+11.78%+201.51% 19.15B
-4.75%+11.27%+85.63%+394.76% 17.68B
-1.59%-1.63%+61.04%+130.75% 17.14B
Average -1.72%+1.14%+41.70%+92.46% 34.21B
Weighted average by Cap. -1.72%+0.36%+33.89%+67.13%

Financials

2026 *2027 *
Net sales 15.87B 13.88B 12.81B 11.83B 22.44B 1,514B 22.82B 153B 60.09B 746B 59.6B 58.3B 2,564B 17.55B 15.35B 14.16B 13.08B 24.81B 1,674B 25.23B 169B 66.43B 824B 65.89B 64.46B 2,834B
Net income 4.06B 3.55B 3.27B 3.02B 5.73B 387B 5.83B 39.09B 15.35B 191B 15.23B 14.9B 655B 5.11B 4.47B 4.12B 3.8B 7.22B 487B 7.34B 49.21B 19.33B 240B 19.17B 18.75B 825B
Net Debt -7.83B -6.85B -6.32B -5.84B -11.08B -747B -11.26B -75.52B -29.66B -368B -29.41B -28.77B -1,265B -10.5B -9.19B -8.47B -7.83B -14.85B -1,002B -15.1B -101B -39.75B -493B -39.43B -38.57B -1,696B
Logo Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows: - revenues from collaboration agreements (51.1%): collaboration with Sanofi (80.3% of revenues), Bayer (19.4%) and other (0.3%); - revenues from product sales (30%); - revenues from sales of technology licenses and subcontracted research services (4.9%). At the end of 2025, the group had a portfolio of approximately 45 products in clinical development.
Employees
15,343
Date Price Change Volume
10/07/26 US$664.52 -0.51% 565,814
09/07/26 US$667.95 +0.76% 672,528
08/07/26 US$662.88 -1.97% 746,834
07/07/26 US$676.23 +4.07% 918,937
06/07/26 US$649.81 -0.68% 714,338
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
667.95USD
Average target price
822.45USD
Spread / Average Target
+23.13%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. REGN Stock